10
Participants
Start Date
November 19, 2015
Primary Completion Date
December 18, 2017
Study Completion Date
December 18, 2017
Rivaroxaban (Xarelto, BAY59-7939)
Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
Vienna
Milan
Madrid
Madrid
Montpellier
Erlangen
Ramat Gan
Barcelona
Izmir
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY